CordenPharma's recent acquisition of AmbioPharm marks a significant advancement in peptide production capacity, enhancing U.S. operations and global reach.

CordenPharma accelerates the expansion of sterile injectable capacity to meet global healthcare demand, investing €80 million in cutting-edge facilities.

CordenPharma is significantly enhancing its sterile injectable manufacturing capabilities in Italy, investing €80 million to achieve a capacity of 500 million injectable units annually.

CordenPharma has acquired AmbioPharm to enhance its peptide manufacturing capacity, aiming to provide advanced solutions for complex peptide APIs worldwide.

CordenPharma has announced a significant investment to enhance its aseptic manufacturing capabilities, aiming for a capacity of 500 million sterile injectables yearly, reinforcing its global leadership.

CDMO CordenPharma expands GLP-1 peptide platform with €500m greenfield manufacturing facility construction near Basel, Switzerland in Muttenz.

Strategic partnership with CordenPharma ensures end-to-end manufacturing capability for Viking's GLP-1/GIP drug VK2735, spanning both injectable and oral formulations with built-in supply redundancy.

Viking partners with CordenPharma to produce billions of VK2735 doses annually. Major manufacturing capacity secured for both oral and injectable obesity treatments ahead of Phase 3 trials.

CordenPharma announces Dr. Jean-Luc Herbeaux as new CEO effective October 1, 2026, succeeding Dr. Michael Quirmbach after significant growth.

CordenPharma announces the appointment of Dr. Jean-Luc Herbeaux as CEO from October 1, 2026, succeeding Dr. Michael Quirmbach after 12 years of transformation.

Long-Term Agreement Secures Dedicated Capacity for Multi-Ton Annual Supply of VK2735 Active Pharmaceutical Ingredient Secures Dedicated Fill/Finish Capacity for 100 Million Annual Autoinjector...

CordenPharma has appointed Dr. Jean-Luc Herbeaux as CEO starting October 1, 2026, succeeding Dr. Michael Quirmbach and aiming for growth.

CordenPharma has appointed Dr. Jean-Luc Herbeaux as CEO, effective October 1, 2026, to spearhead the next growth phase. His leadership marks a new chapter.

CordenPharma announces the appointment of Dr. Jean-Luc Herbeaux as CEO, marking a crucial phase in their growth strategy effective October 1, 2026.

CordenPharma appoints Dr. Jean-Luc Herbeaux as CEO starting October 1, 2026. He succeeds Dr. Michael Quirmbach, a transformative leader for over a decade.

CordenPharma has announced a significant investment to enhance its aseptic filling and packaging operations, increasing capacity to 500 million sterile injectables per year.

CordenPharma has announced a significant investment to boost its aseptic filling capacity to 500 million sterile injectable units per year, reinforcing its market position.

CordenPharma is investing €80 million to enhance its sterile injectable production capabilities, aiming to meet the rising demand for complex medications.

CordenPharma accelerates sterile injectable CDMO manufacturing expansion with €80 million multi-year investment in new facility and additional aseptic fill & finish lines BASEL, Switzerland, Sept. 10, 2026 /PRNewswire/ — CordenPharma continues its ambitious long-term injectable CAPEX program at its FDA & EMA-approved Caponago (Milan), Italy site, reinforcing its position as a global leader in sterile […]